ALS and clinical studies

Amyotrophic lateral sclerosis (ALS) is a rare neurological disease that affects the nerve cells responsible for controlling muscles. Over time, ALS can make it increasingly difficult to move, speak, swallow, and breathe. Although there is currently no cure, researchers around the world are working intensively to better understand the disease and develop more effective treatments.

At Neuro-SysMed, ALS research is a key priority. By combining clinical expertise with cutting-edge research, we aim to uncover the biological mechanisms that drive the disease and translate new discoveries into better care and treatment for patients.

ALS affects people in different ways. Symptoms often begin with weakness in the arms or legs, while some individuals first notice changes in speech or swallowing. The course of the disease varies from person to person, highlighting the need for more personalized approaches to diagnosis and treatment.

In recent years, important advances have been made in our understanding of the genetic and biological factors involved in ALS. These discoveries are helping us identify promising new treatment strategies and biomarkers that may enable earlier diagnosis, better monitoring of disease progression, and more targeted therapies.

Our ALS research aims to:

improve our understanding of the causes and underlying mechanisms of ALS
identify biomarkers that can support earlier diagnosis and more precise disease monitoring
evaluate promising new treatments through clinical studies
accelerate the development of therapies that can slow or alter disease progression
improve quality of life and care for people living with ALS
bring innovative research opportunities to patients in Norway

Through clinical studies, we strive to give patients access to cutting-edge research while contributing to the global effort to develop more effective treatments for ALS in the future.

Neuro-SysMed currently runs the following clinical trials on ALS:

Last updated 7/3/2026